Journal
EXPERT OPINION ON DRUG DELIVERY
Volume 12, Issue 8, Pages 1351-1374Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/17425247.2015.1007949
Keywords
amikacin; aztreonam lysine; biofilms; Burkholderia cepacia complex; colistin; nanoparticles; poly(lactic-co-glycolic acid); Pseudomonas aeruginosa; Staphylococcus aureus; tobramycin
Categories
Funding
- German Ministry of Education and Research (BMBF) [01KI1204, 01EO1002]
- Deutsche Forschungsgemeinschaft, DFG [PL 320/3-1, FT 899/4-1]
Ask authors/readers for more resources
Introduction: Cystic fibrosis (CF) is the most common life-shortening hereditary disease among Caucasians and is associated with severe pulmonary damage because of decreased mucociliary clearance and subsequent chronic bacterial infections. Approximately 90% of CF patients die from lung destruction, promoted by pathogens such as Pseudomonas aeruginosa. Consequently, antibiotic treatment is a cornerstone of CF therapy, preventing chronic infection and reducing bacterial load, exacerbation rates and loss of pulmonary function. Many drugs are administered by inhalation to achieve high pulmonary concentration and to lower systemic side effects. However, pulmonary deposition of inhaled drugs is substantially limited by bronchial obstruction with viscous mucus and restrained by intrapulmonary bacterial biofilms. Areas covered: This review describes challenges in the therapy of CF-associated infections by inhaled antibiotics and summarizes the current state of microtechnology and nanotechnology-based pulmonary antibiotic delivery strategies. Recent and ongoing clinical trials as well as experimental approaches for microparticle/nanoparticle-based antibiotics are presented and their advantages and disadvantages are discussed. Expert opinion: Rapidly increasing antimicrobial resistance accompanied by the lack of novel antibiotics force targeted and more efficient use of the available drugs. Encapsulation of antimicrobials in nanoparticles or microparticles of organic polymers may have great potential for use in CF therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available